Respiratory Distress Syndrome in Premature Infants Clinical Trial
Official title:
Stress Assessment in Preterm Infants With Respiratory Distress Syndrome Treated or Not With an Analgesic Drug During the Traditional or the Less Invasive Method of Surfactant Therapy.
This study will compare stress, changes in oxygenation and oxidative damage in preterm infants with respiratory distress syndrome (RDS) randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) through the traditional (INSURE) or the less invasive (LISA) method.
At present, LISA and INSURE are both used for surfactant therapy in infants as comparable
methods. However, a clear policy of using analgesics during surfactant therapy is still
lacking: some neonatologists use analgesics to reduce stress and pain scores, whereas others
do not approve their use due to interference with spontaneous breathing.
In this open-label, randomized, phase 4 clinical trial, infants admitted to our neonatal
intensive unit care (NICU) will be evaluated according to the selection criteria and then
randomized to receive or not remifentanil as an analgesic drug during the administration of
porcine surfactant (poractant alfa, Curosurf®) via the INSURE or LISA method: Group-1)
LISA-analgesic; Group 2) LISA-no analgesic; Group-3) INSURE-analgesic; Group-4) INSURE-no
analgesic. Study patients will be stratified by gestational age at birth: Block A) 23.0-27.6
weeks of gestation; Block B) 28.0-31.6 weeks of gestation.
Early caffeine administration will be provided according to our NICU guidelines shortly after
birth. Infants with adequate respiratory drive will be stabilized on nasal continuous
positive airway pressure (CPAP; 4-8 cm of water) right after birth. Oxygen saturation targets
will be 90-94%; moderate degrees of hypercarbia (PaCO2 < 60 mmHg, provided arterial pH >7.22)
will be tolerated. Conditions mimicking respiratory distress syndrome (RDS; i.e. sepsis, air
leaks, aspiration pneumonia, congenital heart disease) will be ruled out. RDS diagnosis will
be clinical according to the European Guidelines. Nasal CPAP, bi-level CPAP or nasal
intermittent positive pressure ventilation (synchronized or not) will be used at the
discretion of the attending physician to stabilize the patients. Intubation criteria
according to our NICU guidelines will be:
1. severe acidosis (defined as arterial pH<7.20 with a partial pressure of carbon dioxide
(PaCO2) > 55 mmHg and partial pressure of oxygen (PaO2) < 50 mmHg) with a fraction of
inspired oxygen (FiO2) > 0.50;
2. severe apnoea.
Enrolled infants will be evaluated from birth to day 7 of the hospital stay.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01651637 -
First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome
|
Phase 1 | |
Terminated |
NCT02939742 -
Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?
|
Phase 2/Phase 3 | |
Completed |
NCT02770976 -
Respiratory Pattern During Neurally Adjusted Ventilator Assist (NAVA) in Preterm Infants
|
N/A | |
Completed |
NCT02661256 -
Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates
|
N/A | |
Active, not recruiting |
NCT02445040 -
Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates
|
N/A | |
Completed |
NCT01962818 -
High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance.
|
N/A | |
Completed |
NCT02210026 -
Seattle-PAP Bubble Nasal CPAP and Work of Breathing
|
Phase 1 | |
Not yet recruiting |
NCT02200900 -
Study of Respiratory Physiology During High Flow Nasal Cannula Treatment in Preterm Neonates.
|
N/A | |
Completed |
NCT02396693 -
Successful Extubation and Noninvasive Ventilation in Preterm ≤ 1500g Terms
|
N/A | |
Completed |
NCT01220687 -
Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation
|
N/A |